Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models

Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models

A complete resection of tongue cancer is often difficult. We investigate the usefulness of administering G47Δ (teserpaturev), a triple-mutated oncolytic herpes simplex virus type 1, prior to resection. G47Δ exhibits good cytopathic effects and replication capabilities in all head and neck cancer cel...

Full description

Bibliographic Details
Main Authors: Kosuke Inoue, Hirotaka Ito, Miwako Iwai, Minoru Tanaka, Yoshiyuki Mori, Tomoki Todo
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:Molecular Therapy: Oncolytics
Subjects:
tongue cancer
G47Δ
oncolytic virus therapy
immunotherapy
neoadjuvant therapy
local recurrence
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770523000487

Similar Items

Similar Items